In Re Novartis Pharmaceuticals Corporation, 24-0239, October 24, 2025.
On appeal from Sixth Court of Appeals, Texarkana, Texas.
Synopsis
The Texas Supreme Court denied Novartis’s petition for writ of mandamus and declined to resolve the substantive questions whether the Texas Health Care Program Fraud Prevention Act’s qui tam provisions confer standing on private relators or violate the separation-of-powers provision of the Texas Constitution. The Court expressly deferred those constitutional and standing questions to further development by the new statewide appellate court, leaving the underlying jurisdictional issues unresolved for now.
Relevance to Family Law
Although this is a commercial qui tam dispute, the decision is directly relevant to family-law practitioners who litigate cases involving state actors (DFPS, the attorney general, county/district attorneys) or novel assertions of public interests in private litigation. The opinion reinforces that Texas appellate courts may be reluctant to decide high-stakes jurisdictional or separation-of-powers questions in interlocutory mandamus contexts until lower appellate courts develop a record and reasoned analysis. Family-law litigators should therefore be deliberate about (1) developing a robust trial-court record on standing and state interest where DFPS or the state participates, (2) preserving separation-of-powers and representation-of-the-state arguments, and (3) calibrating interlocutory relief strategy (mandamus vs. interlocutory appeal) in light of evolving appellate assignments and deference to initial fact-development.
Case Summary
Fact Summary
Health Selection Group, LLC (HSG) sued Novartis under the Texas Health Care Program Fraud Prevention Act (the Act), alleging fraudulent schemes that caused significant payments by Texas health-care programs. The State declined to intervene within the statute’s 180-day window, and HSG proceeded as a qui tam relator. Novartis moved to dismiss and filed a plea to the jurisdiction arguing that HSG lacked standing and that the Act’s qui tam provisions violate the separation of powers by enabling a private party to represent the State. The trial court denied Novartis’s motion. Novartis sought mandamus relief from the Sixth Court of Appeals (Texarkana), which denied relief without substantive analysis; the Supreme Court of Texas likewise denied mandamus, issuing a statement by Justices Young and Sullivan explaining the denial and noting the prudence of awaiting the new statewide appellate court’s considered view.
Issues Decided
The Court decided only (procedurally) that mandamus relief was not warranted in this posture. It did not decide the central substantive issues raised by Novartis: (1) whether a qui tam relator under the Act has standing to assert the State’s claim (i.e., whether the relator pleads an injury in fact assignable from the State); and (2) whether the Act’s qui tam device violates Article II, § 1 of the Texas Constitution by effectively permitting a private party to represent the State in court.
Rules Applied
The opinion discusses and places the dispute against (a) the text and structure of the Texas Health Care Program Fraud Prevention Act (formerly the Texas Medicaid Fraud Prevention Act), including Tex. Hum. Res. Code §§ 36.001–.132 and key provisions such as §§ 36.101 (qui tam suits), 36.102 (notice to the attorney general), 36.104 (state takeover/declination), and § 36.052 (civil remedies); (b) Texas precedent treating this statutory scheme as a penalty-driven enforcement regime distinguishable from damage-recovery statutes, principally In re Xerox Corp., 555 S.W.3d 518 (Tex. 2018); (c) federal decisions addressing qui tam standing and separation-of-powers concerns (Vermont Agency of Natural Resources v. United States ex rel. Stevens, 529 U.S. 765 (2000); recent commentary in Polansky and Wis. Bell concurrences/dissents); and (d) Texas constitutional separation-of-powers authorities (Abbott v. Harris County, Tex. Boll Weevil Eradication Found. v. Lewellen, Agey v. Am. Liberty Pipe Line Co.). The Court also applied mandamus standards and recognized the role of appellate allocation (the new statewide appellate court) in resolving novel, statewide constitutional issues.
Application
The Court’s application is primarily procedural and prudential. Rather than addressing the standing and separation-of-powers contentions on the merits in an interlocutory mandamus posture, the Court explained that the presence of a newly constituted statewide appellate court, which has already asserted jurisdiction over similar disputes, counsels judicial restraint. The Court emphasized the benefit of allowing that intermediate appellate body to analyze and articulate reasoned holdings on the novel, complex questions presented—issues that implicate statutory interpretation, the punitive character of the Act, and the allocation of representational authority under the Texas Constitution. The narrative of the opinion thus frames the Supreme Court’s denial as an institutional choice to permit development of considered lower-appellate precedent before the Court addresses questions that may have significant structural and remedial consequences across Texas jurisprudence.
Holding
The Supreme Court of Texas denied the petition for writ of mandamus. In denying relief, the Court did not reach the merits of Novartis’s contentions that HSG lacks standing to sue under the Act and that the Act’s qui tam provisions violate Article II’s separation of powers. Instead, it declined mandamus review in deference to the new statewide appellate court’s opportunity to consider and articulate holdings on those inescapable constitutional and jurisdictional questions.
Practical Application
For family-law practitioners, the decision offers several strategic lessons. First, when litigating against or with a state actor (DFPS, Attorney General, county/district attorneys), anticipate and document the State’s role and any statutory scheme that purports to confer enforcement authority to private parties; a trial record that clarifies whether a private litigant is asserting a private right, an assigned state right, or a public enforcement interest will materially affect appellate reviewability. Second, recognize that high-order constitutional challenges—particularly separation-of-powers claims—may be deferred by higher courts until lower appellate courts frame the issues; thus, build a record and seek comprehensive findings rather than expecting quick interlocutory resolution. Third, calibrate requests for interlocutory relief: mandamus is discretionary and may be denied on prudential grounds where broader statewide implications are involved; consider parallel avenues (certified questions, preservation for definitive appellate review) and tailor immediate relief strategies accordingly. Finally, when the state expresses a continuing interest or appears to reserve intervention rights (e.g., post-declination under a statutory scheme), coordinate filings and preserve objections to representation and standing to provide appellate courts a firm factual and legal basis to resolve jurisdictional questions.
Checklists
Preserve the Record
- Obtain and file all statutory notices and disclosures that the opposing party or state is required to provide.
- Move for specific trial-court findings on who is asserting the State’s interest, whether the State has assigned any right, and the factual basis for claimed injury.
- Include documentary proof of any alleged monetary impact on state programs or lack thereof.
Plead Standing Concretely
- Allege concrete injury in fact where possible; if asserting an assigned state interest, plead the statutory text demonstrating authority to bring the claim.
- Identify and attach statutory provisions relied upon (e.g., §§ 36.101, 36.102, 36.104) and explain how the statute creates a relator’s right to recover penalties in the name of the State.
- Anticipate and refute the argument that the claim is solely one of injury-in-law by tying alleged conduct to financial or programmatic harm to the state where available.
Coordinate with the State
- Serve the attorney general or appropriate state official as required by statute and preserve proof of service.
- Seek written confirmation from the State when it declines or reserves intervention; incorporate the State’s position into motions and findings.
- If the State takes a position supporting or opposing intervention, file a motion to compel clarification or to obtain contemporaneous trial-court rulings on the State’s role.
Frame Separation-of-Powers Arguments
- If asserting a separation-of-powers defense, develop record evidence showing the practical effect of private enforcement on executive prerogatives.
- Request the trial court to make findings about exclusive representational authority and whether a private suit encroaches on statutory or constitutional duties assigned to the Attorney General or prosecutors.
- Preserve objections to any trial-court orders that permit private parties to act in the State’s stead without explicit statutory delegation.
Mandamus and Appellate Strategy
- Before seeking mandamus, evaluate whether the issue is novel and statewide in impact; if so, consider that the Supreme Court may defer to lower appellate development.
- When mandamus is necessary, ensure the record demonstrates clear abuse of discretion or lack of jurisdiction—mandamus relief is not an automatic remedy for difficult legal questions.
- Consider filing interlocutory appeals where permissible and coordinate appellate timing with the emergence of appellate precedent from newly constituted statewide courts.
Citation
In re Novartis Pharmaceuticals Corporation, No. 24-0239 (Tex. Oct. 24, 2025).
Full Opinion
Full opinion (Young & Sullivan, JJ., statement respecting denial of mandamus)
Share this content: